Drug Trial Radar · NCT04930432
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Sep 24, 2021
Primary completion
Apr 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of MCLA-129.
Conditions
- Solid Tumor
- Non-Small Cell Lung Cancer
- Head and Neck Cancer
- Colorectal Cancer
Interventions
MCLA-129Drug
MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT) in Part 1Time frame: First 28 days of treatment
- Maximum Tolerated Dose (MTD) in Part 1Time frame: First 28 days of treatment
- Overall Response Rate (ORR) in Part 2Time frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years
- Treatment-Emergent Adverse Event (TEAE) in Part 1 and 2Time frame: Until 30 days after the last dosing
Locations
87 sites in 1 country. Site status is shown where the registry gives one.
Affiliated Hospital of Hebei University
Baoding, China · Recruiting
Beijing Cancer Hospital
Beijing, China · Recruiting
Beijing Friendship Hospital, Capital Medical University
Beijing, China · Recruiting
Beijing Tongren Hospital
Beijing, China · Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Peking University International Hospital
Beijing, China · Recruiting
The Fifth Medical Center of PLA Ceneral Hospital
Beijing, China · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China · Recruiting
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China · Recruiting
Cangzhou Hospital of Integrated TCM-WM·Hebei
Cangzhou, China · Recruiting
China-Japan Union Hospitai Of Jilin University
Ch’ang-ch’un, China · Recruiting
Ji Lin Cancer Hospital
Changchun, China · Recruiting
Hunan Cancer Hospital
Changsha, China · Recruiting
The Second Xiangya Hospital of Central South University
Changsha, China · Recruiting
Xiangya Hospital of Central South University
Changsha, China · Recruiting
Sichuan Cancer Hospital
Chengdu, China · Recruiting
West China Hospital, Sichuan University
Chengdu, China · Recruiting
Chifeng Municipal Hospital
Chifeng, China · Recruiting
Army Medical Center of PLA
Chongqing, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, China · Recruiting
The First Affiliated Hospital of Dalian Medical University
Dalian, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Fuzhou Pulmonary Hospital of Fujian
Fuzhou, China · Recruiting
The 900 Hospital of the Joint Service Support Force of the People's Liberation Army of China
Fuzhou, China · Recruiting
First Affiliated Hospital Of Gannan Medical University
Ganzhou, China · Recruiting
Guangdong Province Traditional Chinese Medical Hospital
Guangzhou, China · Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China · Recruiting
The Frist Affiliated Hospital of Guangzhou Medical College
Guangzhou, China · Recruiting
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, China · Recruiting
Cancer Hospital affiliated to Harbin Medical University
Ha’erbin, China · Recruiting
Harbin Medical University cancer hospital
Ha’erbin, China · Recruiting
Cancer Hospital of The University of Chinese Academy of Sciences
Hangzhou, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China · Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
Hanzhong Central Hospital
Hanzhong, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
The Second Hospital of Anhui Medical University
Hefei, China · Recruiting
Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)
Henan, China · Recruiting
Inner Mongolia People's Hospital
Hohhot, China · Recruiting
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.